editorial correspondence

What we read

The studio reads editorial mail. We are interested in three kinds of correspondence in particular: factual corrections to anything on the site, pointers to newly published peer-reviewed research on AOD-9604 that we have not yet incorporated, and reasoned source suggestions for adjacent topics we have not yet covered. Briefer is better. A short note with a DOI is more useful to us than a long argument without one.

What we do not respond to

This is a review desk, not a clinic. It does not field questions about obtaining AOD-9604, about whether AOD-9604 suits a particular person or condition, about dosing protocols, vendors, compounding pharmacies, telehealth providers, or anything else that would amount to medical or product advice. It also ignores commercial outreach from research-peptide vendors, supplement companies, and peptide-clinic operators; there are no vendor partnerships and no sponsored content here. None of the contact channels listed below establishes a clinical, prescribing, or counselling relationship.

Contact form

Use the form below to send editorial correspondence. We aim to acknowledge useful notes within a reasonable timeframe but do not commit to individual responses. If you are pointing us to a paper, please include the DOI or PubMed URL in the message body — we will not chase down ambiguous citations.

This is a standing review of the AOD-9604 record. Submissions are read as editorial correspondence only. Nothing sent through this form establishes a clinical, prescribing, or counselling relationship. Do not include personal medical information.